Enisamium Inhibits SARS-CoV-2 RNA Synthesis.
dc.contributor.author | Elli, Stefano | |
dc.contributor.author | Bojkova, Denisa | |
dc.contributor.author | Bechtel, Marco | |
dc.contributor.author | Vial, Thomas | |
dc.contributor.author | Boltz, David | |
dc.contributor.author | Muzzio, Miguel | |
dc.contributor.author | Peng, Xinjian | |
dc.contributor.author | Sala, Federico | |
dc.contributor.author | Cosentino, Cesare | |
dc.contributor.author | Goy, Andrew | |
dc.contributor.author | Guerrini, Marco | |
dc.contributor.author | Müller, Lutz | |
dc.contributor.author | Cinatl, Jindrich | |
dc.contributor.author | Margitich, Victor | |
dc.contributor.author | Te Velthuis, Aartjan JW | |
dc.date.accessioned | 2021-10-30T01:13:03Z | |
dc.date.available | 2021-10-30T01:13:03Z | |
dc.date.issued | 2021-09-17 | |
dc.identifier.issn | 2227-9059 | |
dc.identifier.other | PMC8467925 | |
dc.identifier.other | 34572438 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/330091 | |
dc.description.abstract | Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus disease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on vaccine-induced or naturally acquired protective herd immunity, antiviral strategies are still needed to manage COVID-19. Enisamium is an inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. In vitro, enisamium acts through metabolite VR17-04 and inhibits the activity of the influenza A virus RNA polymerase. Here we show that enisamium can inhibit coronavirus infections in NHBE and Caco-2 cells, and the activity of the SARS-CoV-2 RNA polymerase in vitro. Docking and molecular dynamics simulations provide insight into the mechanism of action and indicate that enisamium metabolite VR17-04 prevents GTP and UTP incorporation. Overall, these results suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis in vitro. | |
dc.language | eng | |
dc.publisher | MDPI AG | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | essn: 2227-9059 | |
dc.source | nlmid: 101691304 | |
dc.subject | Molecular dynamics simulation | |
dc.subject | RNA polymerase | |
dc.subject | Covid-19 | |
dc.subject | Sars-cov-2 | |
dc.subject | Fav00a | |
dc.subject | Amizon | |
dc.title | Enisamium Inhibits SARS-CoV-2 RNA Synthesis. | |
dc.type | Article | |
dc.date.updated | 2021-10-30T01:13:02Z | |
prism.issueIdentifier | 9 | |
prism.publicationName | Biomedicines | |
prism.volume | 9 | |
dc.identifier.doi | 10.17863/CAM.77535 | |
dcterms.dateAccepted | 2021-09-14 | |
rioxxterms.versionofrecord | 10.3390/biomedicines9091254 | |
rioxxterms.version | VoR | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.contributor.orcid | Elli, Stefano [0000-0003-0686-2480] | |
dc.contributor.orcid | Müller, Lutz [0000-0002-3633-1309] | |
dc.contributor.orcid | Te Velthuis, Aartjan JW [0000-0002-5129-3953] | |
dc.identifier.eissn | 2227-9059 | |
pubs.funder-project-id | ZonMw (10430 01 201 0018) | |
pubs.funder-project-id | Wellcome Trust (206579/Z/17/Z) | |
cam.issuedOnline | 2021-09-17 |
Files in this item
This item appears in the following Collection(s)
-
Jisc Publications Router
This collection holds Cambridge publications received from the Jisc Publications Router